Program licensed to:
Regenerative capabilities of cells.
Guided osseous re-modelling process due to scaffold properties.
Excellent integration of newly formed tissue with surrounding tissue.
Clinical Phase II ongoing Q2 2018 with allogenic product.Licensing & co-development agreement with Salvat.
2017: 6 patients treated with Bonecure autologous product and medical discharged as bone consolidation has been achieved.
Recruitment of phase II was completed in 2019.
2018-2020: evaluation of the clinical trial with 6 patients treated with allogeneic Bonecure.